US · TEVA · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Teva Pharmaceutical Industries Limited (TEVA) intrinsic value and stock valuation
$39.23as of 2026-11-21 · Mkt cap 40.44B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Teva Pharmaceutical Industries Limited DCF and intrinsic value
InvestorsCraft values TEVA with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from TEVA’s statements →
Teva Pharmaceutical Industries Limited Graham Number
Graham Number: $13.79d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Natera, Inc. (NTRA) $273.40
- DexCom, Inc. (DXCM) $79.32
- Biogen Inc. (BIIB) $249.59
- Waters Corporation (WAT) $440.45
- Koninklijke Philips N.V. (PHG) $28.61
- Labcorp Holdings Inc. (LH) $367.13
- BioNTech SE (BNTX) $80.96
- STERIS plc (STE) $255.76
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $17.3B | $16.5B | $15.8B | $14.9B | $15.9B |
| Operating income | $2.16B | -$-303M | $433M | -$-2.2B | $1.72B |
| Net income | $1.41B | -$-1.64B | -$-559M | -$-2.45B | $417M |
| EPSd | $1.2M | -$-1.45M | -$-499.55K | -$-2.2M | $376.7K |
| Operating cash flow | $1.65B | $1.25B | $1.37B | $1.59B | $798M |
| Capital expenditure | -$-501M | -$-498M | -$-526M | -$-548M | -$-562M |
| Free cash flow | $1.15B | $749M | $842M | $1.04B | $236M |
| Total assets | $40.7B | $39.3B | $43.5B | $44B | $47.7B |
| Total debt | $17.4B | $18.1B | $20.2B | $21.6B | $23.5B |
| Net debt | $13.8B | $14.8B | $16.9B | $18.8B | $21.3B |
| Total equity | $7.91B | $5.72B | $8.13B | $8.6B | $11.2B |
| Cash and short-term investments | $3.56B | $3.3B | $3.23B | $2.8B | $2.17B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $17.3B | $16.5B | $15.8B | $14.9B | $15.9B |
| Cost of revenue | $8.32B | $8.48B | $8.2B | $7.95B | $8.28B |
| Gross profit | $8.94B | $8.06B | $7.65B | $6.97B | $7.59B |
| Research and development expenses | $1.01B | $1.06B | $953M | $838M | $1.09B |
| Selling, general and administrative expenses | $3.97B | $3.7B | $3.5B | $3.45B | $3.53B |
| Other expenses | $1.79B | $3.61B | $2.76B | $4.89B | $1.26B |
| Operating expenses | $6.78B | $8.37B | $7.21B | $9.17B | $5.88B |
| Cost and expenses | $15.1B | $16.8B | $15.4B | $17.1B | $14.2B |
| Interest income | $0.00 | $0.00 | $68M | $0.00 | $0.00 |
| Interest expense | $916M | $941M | $1.03B | $930M | $891M |
| Depreciation and amortization | $1B | $1.06B | $1.15B | $1.31B | $1.33B |
| Ebitda | $3.14B | $4.43B | $1.56B | -$-925M | $4.41B |
| Operating income | $2.16B | -$-303M | $433M | -$-2.2B | $1.72B |
| Total other income/expenses, net | -$-919M | -$-980M | -$-1.06B | -$-945M | -$-1.05B |
| Income before tax | $1.24B | -$-1.28B | -$-622M | -$-3.14B | $667M |
| Income tax expense | -$-180M | $676M | -$-7M | -$-643M | $211M |
| Net income | $1.41B | -$-1.64B | -$-559M | -$-2.45B | $417M |
| Weighted average shares outstanding | $1.15B | $1.13B | $1.12B | $1.11B | $1.1B |
| Weighted average diluted shares outstanding | $1.17B | $1.13B | $1.12B | $1.11B | $1.11B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $3.56B | $3.3B | $3.23B | $2.8B | $2.17B |
| Net receivables | $3.71B | $3.06B | $3.41B | $3.7B | $4.53B |
| Inventory | $3.18B | $3.01B | $4.02B | $3.83B | $3.82B |
| Total current assets | $13.9B | $12.6B | $12.5B | $12.1B | $12.6B |
| Property, plant and equipment, net | $4.42B | $4.95B | $6.15B | $6.16B | $6.48B |
| Goodwill and intangible assets | $19.8B | $19.6B | $22.6B | $23.9B | $27.5B |
| Long-term investments | $0.00 | $0.00 | $8M | $0.00 | $0.00 |
| Total non-current assets | $26.8B | $26.8B | $31B | $32B | $35.1B |
| Total assets | $40.7B | $39.3B | $43.5B | $44B | $47.7B |
| Accounts payable | $2.53B | $2.2B | $2.6B | $1.89B | $1.69B |
| Short-term debt | $1.82B | $1.78B | $1.67B | $2.11B | $1.43B |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $13.5B | $12.8B | $12.2B | $11.5B | $11B |
| Long-term debt | $15.6B | $16.3B | $18.5B | $19.5B | $22B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $19.4B | $20.8B | $23.1B | $23.9B | $25.4B |
| Capital lease obligations | $288M | $296M | $320M | $349M | $416M |
| Total liabilities | $32.8B | $33.6B | $35.4B | $35.4B | $36.4B |
| Common stock | $58M | $58M | $57M | $57M | $57M |
| Retained earnings | -$-13.76B | -$-15.17B | -$-13.53B | -$-12.98B | -$-10.53B |
| Accumulated other comprehensive income (loss) | -$-2.39B | -$-3.15B | -$-2.7B | -$-2.84B | -$-2.68B |
| Total equity | $7.91B | $5.72B | $8.13B | $8.6B | $11.2B |
| Total investments | $0.00 | $0.00 | $8M | $0.00 | $0.00 |
| Total debt | $17.4B | $18.1B | $20.2B | $21.6B | $23.5B |
| Net debt | $13.8B | $14.8B | $16.9B | $18.8B | $21.3B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $1.42B | -$-1.96B | -$-615M | -$-2.5B | $456M |
| Depreciation and amortization | $1B | $1.06B | $1.15B | $1.31B | $1.33B |
| Stock-based compensation | $157M | $123M | $121M | $124M | $119M |
| Change in working capital | -$-1.37B | -$-435M | -$-72M | $1.36B | -$-1.7B |
| Accounts receivable | -$-173M | $245M | $12M | $334M | -$-574M |
| Inventory | $152M | $166M | -$-147M | -$-163M | $380M |
| Accounts payable | -$-15M | $258M | $1.59B | $2.01B | $764M |
| Net cash provided by operating activities | $1.65B | $1.25B | $1.37B | $1.59B | $798M |
| Investments in property, plant and equipment | -$-501M | -$-498M | -$-526M | -$-548M | -$-562M |
| Acquisitions, net | $34M | $28M | $68M | $61M | $1.96B |
| Net cash used for investing activities | $737M | $792M | $968M | $656M | $1.52B |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-2.15B | -$-1.79B | -$-1.91B | -$-1.49B | -$-2.17B |
| Net change in cash | $256M | $73M | $393M | $636M | $21M |
| Cash at end of period | $3.56B | $3.3B | $3.23B | $2.83B | $2.2B |
| Operating cash flow | $1.65B | $1.25B | $1.37B | $1.59B | $798M |
| Capital expenditure | -$-501M | -$-498M | -$-526M | -$-548M | -$-562M |
| Free cash flow | $1.15B | $749M | $842M | $1.04B | $236M |
Line items
Line items
Line items
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
- CEO
- Richard D. Francis
- Employees
- 37K
- Beta
- 0.86
Explore
Frequently asked questions
What is the intrinsic value of Teva Pharmaceutical Industries Limited (TEVA)?
Teva Pharmaceutical Industries Limited (TEVA) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is TEVA undervalued?
TEVA trades at a price of $39.23 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.